Anti-HCV denotes antibody to hepatitis C virus; HIV denotes human immunodeficiency virus; AIDS denotes acquired immunodeficiency syndrome.
* For 1997 and 1999, included patients treated, or staff members working, at the end of the year. For 1995, included staff and patients from throughout the year.
INTRODUCTION
The Centers for Disease Control and Prevention (CDC) has been conducting surveillance of hemodialysis-associated hepatitis since the early 1970s (1), when CDC reported that the incidence of HBV infection among patients and staff during 1972-1974 had increased by more than 100%, to 6.2% and 5.2%, respectively. These early surveys had only a 50% to 65% response rate of centers listed by the National Dialysis Registry. In an effort to obtain a higher response rate, and thus more complete information, CDC initiated a cooperative program with the Health Care Financing Administration (HCFA) in 1976 that provided for a questionnaire from CDC to be included in HCFA's annual facility survey. As a result of this collaboration, the response rates to the CDC questionnaire now exceed 90%.
Since collaboration with HCFA was begun, the CDC survey has been performed for calendar years 1976, 1980, 1982 to 1997, and 1999 (2-12) . Other hemodialysis-associated diseases and practices not related to hepatitis have been included over the years, and the questionnaire is continually updated to collect data about hemodialysis practices and hemodialysis associated diseases of current interest and importance. The objectives of this yearly survey are to (a) determine the frequency with which certain hemodialysis practices are used, including measures designed to prevent disease, (b) determine the frequency of hemodialysis-associated complications and diseases, and (c) use this information to suggest further measures to prevent complications and disease in hemodialysis patients and staff.
METHODS
In conjunction with the annual facility survey performed by HCFA for calendar year 1999, of the survey year; in previous years, the questions referred to patients and staff present in the unit at any time during the year.
In 1999, the incidence of hepatitis B virus (HBV) infection was defined as the number of patients who became positive for HBsAg during 1999 divided by the number of patients treated at the facility during December 6-11, 1999 ; in effect, the number of patients treated during the oneweek period in December 1999 was used as an estimate of the average census at that dialysis center during 1999. In previous years, the denominator for this incidence rate was the total number of patients treated at the facility at any time during the year.
The prevalence rates of chronic HBV infection and immunity were defined as the percentage of all patients or staff present in the facility during December 6-11, 1999, who were positive for HBsAg or anti-HBs, respectively. All patients or staff (regardless of their susceptibility to HBV infection) were included in calculations of the incidence and prevalence of HBV infection. Among groups of dialysis centers, the median percent of patients receiving vancomycin in December 1999 was calculated by weighting each dialysis center by the number of patients treated.
Information on dialysis center location and ownership was obtained from the HCFA End The numbers of patients and staff members reflect the numbers present during a one-week period in December of the year.
* Data not available.
During 1985-1999, the proportion of freestanding (i.e., located outside the hospital) centers increased from 56% to 80%, and the proportion of centers operating for profit increased from 46%
to 75% (Table 3) . 
Dialyzer Types
During December [6] [7] [8] [9] [10] [11] 1999 , the most common dialyzer types were high flux polysulfone (e.g., F60, F80, 50% of patients) and low flux polysulfone (e.g., F5, F8; 20.9% of patients) ( Table 4 ). 
Dialyzer Reuse
During 1976-1997, the percentage of centers that reported reuse of disposable dialyzers increased from 18% to 82%, but decreased slightly to 80% in 1999 (Table 5 ). Although dialyzer reuse has been implicated in numerous outbreaks, this practice is safe if performed according to recognized protocols (14, 15) . 
Methods Used for Reprocessing Dialyzers
During 1983-1999, the proportion of centers using formaldehyde for reprocessing dialyzers decreased from 94% to 33%, while the proportion using a peracetic acid product increased from 5% to 58% (Table 6 ). In 1999, 3% of centers used heat to disinfect dialyzers between reuses. 
Vascular Access Types
During December 6-11, 1999, 51.9% of patients received dialysis through an arteriovenous graft, 26.0% through an arteriovenous fistula, and 22.2% through a temporary or permanent central catheter (Table 7) . Since 1995, the percent of patients receiving dialysis through catheters increased from 12.7% to 22.2%.
In 1999, 25.6% of catheters were used for new patients awaiting an implanted access (i.e., a fistula or graft), 27.3% for established patients with a failed access awaiting a new implanted access, 42.2% as an access of last resort, and 6.6% for other reasons, including patient preference.
Among the 18 ESRD networks designated by HCFA (see Methods), use of fistulas (the most desirable access type) ranged from 18.3% to 38.2% (Table 8 ). The estimated risk of access- Rows are sorted by this estimate.
Use of Pneumococcal Vaccine
In 1999, pneumococcal vaccine was offered to patients at 64.5% of centers, which included 18.4% of centers with <25% of patients vaccinated, 10.9% with 25-49% vaccinated, 11.0% with 50-74% vaccinated, 17.1% with $75% vaccinated, and 7.1% with percent vaccinated unknown.
The percent of patients vaccinated was estimated by assuming that 0% of patients were vaccinated at centers not offering the vaccine, 12.5% were vaccinated at centers with <25% vaccinated, 37.5% at centers with 25-49% vaccinated, 67.5% at centers with 50-74% vaccinated, and 87.5% at centers with $75% vaccinated. Overall, the estimated percent vaccinated was 28.9%
(range 12.5%-41.6% among the ESRD Networks, Table 9 ). 
Use of Influenza Vaccine
In 1999, influenza vaccine was offered to patients at 95.1% of centers, which included 4.4% of centers with <25% of patients vaccinated, 9.6% with 25-49% vaccinated, 24.5% with 50 74% vaccinated, 53.3% with $75% vaccinated, and 3.3% with percent vaccinated unknown (Table 10 ). The percent of patients vaccinated was estimated using methods similar to that outlined under "Use of Pneumococcal Vaccine." Overall, the estimated percent vaccinated was 67.4% (range 54.9-74.7% among the ESRD networks, Table 10 ). 
Use of Hepatitis B Vaccine
In 1999, policies for vaccination of chronic hemodialysis patients were as follows: 94.6% of centers offered vaccine to patients; in 1.7% of centers vaccine was offered at individual physician's offices; 2.2% of centers did not offer vaccine to patients; and 1.6% of centers reported other policies.
During 1983-1999, the proportion who had ever received at least three doses of hepatitis B vaccine increased from 5% to 55% among patients and from 26% to 88% among staff ( Table 11 ).
Note that the survey questions on vaccination of patients and staff were changed for the 1997 and 1999 surveys. During 1983-1996, the percent of patients vaccinated was calculated as the number of vaccinated patients treated at any time during the year divided by the total number of patients treated at any time during the year. In 1997 and 1999, the percent of patients vaccinated was calculated as the number of vaccinated patients who were present during a one-week period in
December divided by the total number of patients present during the same one-week period in
December. Similar methods were used to calculate the percents of staff vaccinated during the two time periods (1983-1996 vs 1997-1999 ). The vaccination data may be more accurate for 1997 and 1999 than for previous years, since determination of vaccine status in December of the year, at the time the survey is completed, should be more accurate than determining vaccine status for patients treated (or staff members who worked) at any time during the year, as was requested in previous surveys. 
Prevalence of Antibody to Hepatitis B Surface Antigen (anti-HBs)
During 1980-1999, the prevalence of anti-HBs among patients increased from 11.3% to 36.8% (Table 13 ). The presence of anti-HBs indicates immunity to HBV infection, either from vaccination or as a result of recovery from infection with natural infection (17). 
Incidence and Prevalence of HBV Infection
In 1999, 80.4% of centers reported screening susceptible patients monthly for HBsAg, 0.7% bimonthly, 13.2% quarterly, 4.2% semiannually, and 1.4% other or none.
During 1976-1999, the incidence of HBV infection in patients decreased from 4.4% to 0.06%, with the largest decline occurring during 1976-1980 ( Table 14 ). Note that in 1999 the denominator for the HBsAg incidence rate was the number of patients treated during a one-week period in December of the year, while in prior years it was the number of patients treated throughout the year.
During 1976-1999, the prevalence of HBsAg-positivity among patients declined from 7.8% to 0.9% (Table 14) .
In 1999, 3.3% of centers reported $1 patients with newly acquired (incident) HBV infection, 24.1% of centers reported $1 patients with chronic (prevalent) HBV infection, and 25.5% of centers reported $1 patients with either acute or chronic HBV infection.
This national surveillance project was initiated primarily because of the high incidence of HBV infection reported among hemodialysis patients and staff in the early 1970s (1).
Hemodialysis patients may acquire HBV infection from community sources or from transmission in hemodialysis centers due to inadequate infection control precautions (18) (19) (20) or to accidental breaks in technique (21) . Factors contributing to the decline in HBV infection since the 1970s have been previously reviewed (9). 
Hepatitis C
In 1999, 56% of centers tested patients for anti-HCV, and the prevalence of anti-HCV at these centers was 8.9%; 36% of centers tested staff for anti-HCV, and the prevalence of anti-HCV at these centers was 1.9% (Table 15 ). Among centers that tested for anti-HCV, 12.2% reported having $1 patients who became anti-HCV positive in 1999 (i.e., tested positive for anti-HCV in 1999 and had previously tested negative).
Anti-HCV prevalence among patients was similar at centers that reused (8.9%) and did not reuse (8.5%) dialyzers (p=0.6 controlling for center size). Anti-HCV prevalence among staff was similar at centers that reused (2.0%) and did not reuse (1.8%) dialyzers (p=0.4).
Among centers that reused dialyzers, 1,973 (72.4%) reused them on patients that were anti-HCV positive, 406 (14.9%) did not reuse them on anti-HCV positive patients, and 348 (12.8%)
did not have any anti-HCV-positive patients. The prevalence of anti-HCV was higher at centers that reused vs those that did not reuse dialyzers on anti-HCV-positive patients (9.4% vs 7.9%, p=0.012 controlling for center size and ESRD network). The percent of centers with $1 patients who became anti-HCV positive in 1999 was higher among centers that reused dialyzers on anti-HCV positive patients (13.8%) than on centers that did not (10.1%, p=0.1), but the difference was not statistically significant. Since reprocessed dialyzers are reused on the same patient, it is unclear why reuse would be associated with higher rates of HCV infection among patients. This association could be due to unmeasured confounding factors or related to environmental contamination resulting from improper handling (e.g., transport of used dialyzers to a reprocessing area without placing them in leakproof containers). Among the ESRD networks, anti-HCV prevalence ranged from to 5.6 to 11.3% (Table   16 ). 
Place of Preparation of Injectable Medications
In 1999, medications from multidose vials were most commonly drawn into syringes in preparation for patient administration in a separate medication room or in a medication area separate from the dialysis stations (72.3% of centers), at the dialysis stations (10% of centers), or on a medication cart which is wheeled from patient dialysis station to dialysis station (17.8% of centers).
The place where medications were drawn up was not associated with HBV incidence.
However, use of a medication cart was associated with a higher anti-HCV prevalence and with a larger percent of centers with $1 patients who became anti-HCV positive in 1999 (Table 17 ). 
Vancomycin Use
The median percent of patients receiving vancomycin in December decreased from 5.6%
in 1995 to 4.3% in 1999 (Table 18 ). In 1999, vancomycin use varied among the ESRD networks from 2.4% of patients in network 17 to 5.8% of patients in network 7 (Table 19 ). 
Antimicrobial Use Policies
In 1999, 93.6% of centers reported using $1 measures to encourage judicious antimicrobial use. Antimicrobial use policies included: the reason for the antimicrobial must be recorded in the patient's chart or on an order form, 63.9% of centers; a written policy on antimicrobial use, 41.7% of centers; automatic stop order (i.e., antimicrobials must be reordered at intervals), 30.8% of centers; formulary restriction (i.e., only selected antimicrobials are available), 30.5% of centers;
and approval needed for certain antimicrobials, 23.6% of centers.
The median percentage of patients receiving vancomycin in December 1999 was slightly lower at centers having a written policy on antimicrobial use (4.1%) than at centers not having such a policy (4.5%, p=0.048). There were no significant differences in vancomycin use associated with other antimicrobial use measures (data not shown).
Vancomycin-Resistant Enterococci (VRE)
In 1999, the number of patients with known VRE was as follows: no known patients with VRE, 65.9% of centers; 1-4 patients with VRE, 31.6% of centers; 5-9 patients with VRE, 1.9% of centers; and $10 patients with VRE, 0.5% of centers. At centers having $1 VRE-positive patients, VRE-positive patients were never treated in a separate room at 64.4% of centers, sometimes in a separate room at 13.5% of centers, and always in a separate room at 22.2% of centers. Rectal swab or stool cultures to check for VRE were done at 6% of centers.
The percentage of centers reporting $1 patients with VRE increased from 11.5% in 1995 to 34.1% in 1999 (Table 20) . Among the ESRD networks, reporting of VRE varied from 14.0%
(network 16) to 62.1% (network 1; Table 21 ).
The data reported here on treatment of VRE patients are limited in that the survey does not distinguish between clinical infection and colonization (i.e., positive culture for the organism without invasive infection). Centers that perform surveillance for VRE with stool or rectal cultures, or that treat patients from hospitals where such culturing is done, would be more likely to report VRE-colonized patients, introducing "surveillance bias." 
Human Immunodeficiency Virus Infection
During 1985-1999, the percentage of centers that reported providing dialysis for patients with HIV infection increased from 11% to 36% (Table 22) In 1999, 1.4% (range among the networks, 0.4%-3.1%) of patients were reported to have HIV infection and 0.5% (range among the networks, 0.1%-1.0%) to have AIDS (Table 23) . 
DIALYSIS POLICIES AND PRACTICES
10. During December 6-11, 1999 , how many of your hemodialysis patients were treated with these dialyzer types: (write in the number of patients) a. High flux polysulfone (e. g. F60-F80 
"
Give special attention to cleaning control panels on the dialysis machines and other surfaces that are frequently touched and potentially contaminated with patients' blood.
Discard all fluid and clean and disinfect all surfaces and containers associated with the prime waste (including buckets attached to the machines).
!
For dialyzers and blood tubing that will be reprocessed, cap dialyzer ports and clamp tubing. Place used dialyzer and tubing in a leak-proof container for transport from station to reprocessing or disposal area 
Dialyze HBsAg-positive patients in a separate room using separate machines, equipment, instruments, and supplies.
Staff members caring for HBsAg-positive patients should not care for HBV susceptible patients at the same time (e.g., during the same shift or during patient change-over). 
Routine serologic testing for hepatitis B virus (HBV) and hepatitis C virus (HCV) (A1)
Patient
Other infection control topics
! Guidelines for vascular access use and preventing access-associated infections (A3, A4).
! Chronic hemodialysis patients should receive pneumococcal vaccine every 5 years and influenza vaccine every year (A5).
! Recommendations for prudent vancomycin use have been made by CDC and the Hospital Infection Control Practices Advisory Committee (A6). Cefazolin, a first-generation cephalosporin, may be substituted for vancomycin in some instances (A7).
